• fewer cold sores means more freedom to get close

TARGETED COLD SORE TREATMENT¹

 

Fewer Recurrences. More Freedom.

Cold sores are a sore subject for many, which is why new Sitavig (acyclovir), 50mg Muco-Adhesive Buccal Tablet is such a breakthrough in the world of cold sore treatments.

Sitavig is a single-dose prescription cold sore treatment that may stop cold sores before they start, which means fewer outbreaks and a lot more freedom.¹

 

The freedom to live your life — with fewer cold sores.¹

Knowledge is freedom when it comes to cold sores. Know your triggers and stop cold sore outbreaks before they happen¹ — so you have the freedom to get on with your life.

What will you do more of with fewer cold sore outbreaks?

 

Additional cold sore resources:

References

  1. Bieber T, Chosidow O, Bodsworth N, Tyring S, Hercogova J, Bloch M, Davis M, Lewis M, Boutolleau D, Attali P and the LIP Study Group. Efficacy and safety of acyclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP): A double-blind, placebo-controlled, self-initiated trial. J Drugs Dermatol. 2014;13(7):791-798. View study (link will lead you to the JDD site).
Indication & Important Safety Information
INDICATION
Sitavig® (acyclovir), 50mg Muco-Adhesive Buccal Tablet is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults.

IMPORTANT SAFETY INFORMATION

Sitavig should not be used in patients with known hypersensitivity to acyclovir, milk protein concentrate, or other components of the product.

Sitavig has not been studied in pregnant women or in immunocompromised patients and no interaction studies have been performed. Sitavig’s safety and efficacy have not been established in pediatric patients.

Sitavig is a Pregnancy Category B product; therefore it should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. It is not known if Sitavig is excreted in breast milk; however, systemic absorption is minimal.

In a controlled clinical trial Sitavig’s most common side effects (greater than or equal to 1%) were:
headache (3%), dizziness (1%), lethargy (1%), gingival (gum) pain (1%), aphthous stomatitis (canker sores) (1%), application site pain (1%), application site irritation (1%), erythema (1%) and rash (1%). In the same trial these side effects ranged from 0%-3% for placebo.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch.com or call 1-800-FDA-1088.

Click here for Full Prescribing Information.